tbuckley/cabot-search huggingface dataset:
Phenylalanine Mustards
Authors: Geoffrey Falkson
Journal: JAMA (1967)

<h3>To the Editor:—</h3> InThe Journal(<b>200</b>, May 15, 1967, adv p 223) a review of our article "A Clinical Trial With Sarcolysin" (<i>S Afr Med J</i><b>41</b>:224, 1967) was published. We wish to draw your attention to the erroneous use of the name "melphalan" in your review. Our article reported a clinical trial with the DL isomer of 3-[p-[bis-(2-chloroethyl) amino] phenyl ] L-alanine hydrochloride, also known as "sarcolysin," merphalan, CB-3007, sarcochlorin, DL-phenylalanine mustard, and PAM, with the NSC number 14210. Your reviewer mistakenly reported that our trial was with "melphalan," the L isomer. While we have used melphalan for several years in the treatment of malignant neoplasms, a limited supply of sarcolysin was only made available to us in 1964. This was used in a clinical trial on six patients with reticulum cell sarcoma, seven with Kaposi's sarcoma, three with osteogenic sarcoma, and three with seminoma. Sarcolysin has been
Comparative effectiveness of nivolumab versus regorafenib for hepatocellular carcinoma patients who experienced sorafenib failure
Authors: Yun Bin Lee, Cheol-Hyung Lee, Minseok Albert Kim, Heejoon Jang, Hyunwoo Oh, Sun Woong Kim, Eun Ju Cho, Kyung-Hun Lee, Jeonghoon Lee, Su Jong Yu, Jung-Hwan Yoon, Tae-You Kim, Yoon Jun Kim
Journal: Journal of Hepatology (2020)
WATCH MEDICAL LEGISLATION.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical ethics: biomedical ethics at the bedside
Authors: E. D. Pellegrino
Journal: JAMA (1988)

The articles chosen for this issue of<i>JAMA</i>illustrate various aspects of clinical ethics, the emergent genre of medical ethics that focuses on the process of ethical decision making in its clinical setting. Clinical ethics moves ethics from its place in the classroom and ethicist's study to its origins at the bedside of sick people, where the dilemmas the ethicist contemplates are generated and where ethical discussion ultimately must end in decision and action.<sup>1,2</sup> These articles describe how the move to the bedside is reshaping the way medical ethical decisions are made in the hospital, the clinic, and the physician's office. In democratic, educated, and morally heterogeneous societies like ours, the intuitive and idiosyncratic way of making ethical choices is no longer tenable. Medical ethics has become a public affair. The physician's decisions must now be justified to patients and their families, one's colleagues, and the courts. As a
The Elixir of Life and the Secret of Perennial Youth
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Clinical Recognition and Management of Patients Exposed to Biological Warfare Agents
Authors: David R. Franz
Journal: JAMA (1997)

Concern regarding the use of biological agents—bacteria, viruses, or toxins—as tools of warfare or terrorism has led to measures to deter their use or, failing that, to deal with the consequences. Unlike chemical agents, which typically lead to violent disease syndromes within minutes at the site of exposure, diseases resulting from biological agents have incubation periods of days. Therefore, rather than a paramedic, it will likely be a physician who is first faced with evidence of the results of a biological attack. We provide here a primer on 10 classic biological warfare agents to increase the likelihood of their being considered in a differential diagnosis. Although the resultant diseases are rarely seen in many countries today, accepted diagnostic and epidemiologic principles apply; if the cause is identified quickly, appropriate therapy can be initiated and the impact of a terrorist attack greatly reduced.
如果更多的人定期涂抹防晒霜,则黑色素瘤预防率能达到多少?
Authors: C.M. Olsen, L.F. Wilson, A.C. Green, N. Biswas, J. Loyalka, D.C. Whiteman
Journal: British Journal of Dermatology (2018)

恶性黑色素瘤是较常见皮肤癌中风险系数最高的疾病,每年造成数千人死亡。近几十年来,黑色素瘤在西方国家/地区愈发常见。暴露于太阳紫外线是导致黑色素瘤的主要环境因素。日晒前涂抹防晒霜已经证明能够降低黑色素瘤的患病风险。该研究由澳大利亚布里斯班以及英国曼彻斯特的癌症流行病学家联合开展,旨在探索更好地坚持使用防晒霜对今后生活的潜在影响。研究对象包括澳大利亚人以及美国的白种人,原因在于此类人群的黑色素瘤发病率很高,而且存在关于此类人群的黑色素瘤发病率以及当前防晒霜使用情况的可靠比较数据,方便研究者作出推测。通过合适的计算机建模工具,该研究表明如果坚持增加使用防晒霜(从 2012 年起连续十年每年增加 5%,这是实际可行的),则到 2031 年,美国和澳大利亚的恶性黑色素瘤发病率分别可以降低 11% 和 10%。相比之下,如有防晒霜最高用量(所有人在使用防晒霜后直接见效),则到 2031 年,美国和澳大利亚的黑色素瘤发病率分别可以降低 38% 和 34%。虽然该研究中的黑色素瘤发病率的潜在降低比率相当令人失望,不过这也表明如果更好地坚持使用防晒霜,每年可能挽救数千条生命。
Coping With Calamity
Authors: Emily Friedman
Journal: JAMA (1994)

On August 17,1969, Hurricane Camille, the most destructive North American hurricane since 1937, made landfall on the Gulf Coast. The storm devastated coastal Mississippi, Louisiana, and Alabama and inland areas in the South. It killed between 250 and 400 people and caused damage estimated at $1 billion, a stunning sum at the time. The 25th anniversary of that catastrophe is cause enough to ask how much has been learned about disaster planning since; but the United States and its health care system have had several more recent unfortunate opportunities to consider the question. Among these trials have been Hurricane Andrew in south Florida on August 24,1992; Hurricane Iniki on the Hawaiian island of Kauai on September 11,1992; massive flooding in the Midwest in the summer of 1993; and the Northridge earthquake in the San Fernando Valley of southern California on January 17,1994. In each case, health care facilities suffered problems—in
Mortality in Workers Exposed to Electromagnetic Fields
Authors: Samuel Milham
Journal: Environmental Health Perspectives (1985)

In an occupational mortality analysis of 486,000 adult male death records filed in Washington State in the years 1950-1982, leukemia and the non-Hodgkin's lymphomas show increased proportionate mortality ratios (PMRs) in workers employed in occupations with intuitive exposures to electromagnetic fields. Nine occupations of 219 were considered to have electric or magnetic field exposures. These were: electrical and electronic technicians, radio and telegraph operators, radio and television repairmen, telephone and power linemen, power station operators, welders, aluminum reduction workers, motion picture projectionists and electricians. There were 12,714 total deaths in these occupations. Eight of the nine occupations had PMR increases for leukemia [International Classification of Diseases (ICD), seventh revision 204] and seven of the nine occupations had PMR increases for the other lymphoma category (7th ICD 200.2, 202). The highest PMRs were seen for acute leukemia: (67 deaths observed, 41 deaths expected; PMR 162), and in the other lymphomas (51 deaths observed, 31 deaths expected; PMR 164). No increase in mortality was seen for Hodgkin's disease or multiple myeloma. These findings offer some support for the hypothesis that electric and magnetic fields may be carcinogenic.
Fixed-Dose Unfractionated Heparin vs Low-Molecular-Weight Heparin for Venous Thromboembolism
Authors: Huichun Zhan, Haoyi Zheng
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Highlights
Journal: JAMA Dermatology (2014)

Staging of cSCC as Predictor of Sentinel Lymph Node Biopsy Results 19Nodal metastases from cutaneous squamous cell carcinoma (cSCC) are rare.Identifying patients at greatest risk remains a challenge because clear prognostic data are lacking.In this case series, Schmitt et al evaluate patients with nonanogenital cSCC having sufficient tumor characteristics to allow staging and who underwent sentinel lymph node (SLN) biopsy.A positive SLN was identified in 12.3% of all patients, mostly in those with T2 lesions.Sentinel lymph node biopsy accurately identifies SLNs and is well tolerated, although the survival benefit of early detection of subclinical nodal metastases remains unknown.
SMALLPOX
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The Purin Bodies of Foodstuffs and the Rôle of Uric Acid in Health and Disease.
Journal: JAMA (1904)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Persons With, Without Health-Care Coverage
Journal: JAMA (1991)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
From the Centers for Disease Control. FDA approval of use of diphtheria and tetanus toxoids and acellular pertussis vaccine
Journal: JAMA (1992)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
HEAVY BREASTS AS A FACTOR IN THE PRODUCTION OF FAULTY POSTURE
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Incorrect Information
Authors: Tero Kivela, Risto Pelkonen, Olli Heiskanen, Bartholinus Cl, D Petri, Pawij Observationes, Anatomicae Selectiores, Petrus Morsing, T Marsha, George Wallace
Journal: JAMA (1998)

of which is "to bring into harmony or proportion," and it could denote here balance between humors that "tend upward" and those that do not.We hope that Dr Van Nuis, who is apparently of Dutch ancestry, will forgive us for mixing the years of the councils of Trent and Utrecht, both of which were crucial events in Dutch history.Van Nuis' comments are an excellent reminder that writers can never be too careful, and we are most relieved that he has rectified our lapsus calami so rapidly.
Mesantoin Lymphadenopathy Morphologically Simulating Hodgkin's Disease
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Counseling the Handicapped: A Manual on Aptitudes and Their Discovery and Interpretation
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 3051: Targeting cdk12/13 re-sensitizes trastuzumab resistant her2+ breast cancers
Authors: Francesca Vena, Max Aceti, Simon Bayle, Victor Quereda, Andrii Monastyrskyi, William Roush, Derek Duckett
Journal: Cancer Research (2019)

Abstract Overexpression or amplification of the human epidermal growth factor receptor 2 (erbB2), which encodes for a receptor tyrosine kinase often referred to as HER2, occurs in about 20% breast cancer patients and is associated with aggressive disease and poor clinical outcome. The anti-HER2 therapy trastuzumab (a monoclonal antibody targeting HER2) has proven highly effective, increasing relapse free and overall survival for HER2 positive breast cancer patients. Nevertheless, acquisition of therapeutic resistance occurs frequently in advance disease. Recent studies have demonstrated that HER2 co-amplified genes may play a role in mechanisms of disease resistance. Cyclin dependent kinase 12 (CDK12) is among the genes that have been reported to be amplified in addition to HER2, and thus we aimed to investigate whether targeting CDK12 could be exploited as a therapeutic target and enhance and/or restore sensitivity in HER2 positive inhibitor resistant models of breast cancer. We have developed an in-house, highly selective, potent, and orally bioavailable CDK12/13 inhibitor, which effectively blocks proliferation and induces apoptosis in a panel of breast cancer cell lines and acts in synergy with trastuzumab in HER2 treatment resistant cell lines. Furthermore, our lead compound significantly slows tumor growth in trastuzumab resistant patient derived xenograft (PDX) models (as a single agent) and importantly, provokes greater efficacy in combination with trastuzumab. We are beginning to identify the signaling pathways underlying HER2 positive treatment resistance and how inhibition of CDK12/13 thwarts these resistance mechanisms. Accordingly, we anticipate that the development of CDK12/13 inhibitors holds promise as an anti-breast cancer strategy and future treatment option for HER2 positive breast cancer patients with recurrent disease. Citation Format: Francesca Vena, Max Aceti, Simon Bayle, Victor Quereda, Andrii Monastyrskyi, William Roush, Derek Duckett. Targeting cdk12/13 re-sensitizes trastuzumab resistant her2+ breast cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3051.